211 related articles for article (PubMed ID: 30474722)
1. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.
Meier A; Veeraraghavan H; Nougaret S; Lakhman Y; Sosa R; Soslow RA; Sutton EJ; Hricak H; Sala E; Vargas HA
Abdom Radiol (NY); 2019 Jun; 44(6):2040-2047. PubMed ID: 30474722
[TBL] [Abstract][Full Text] [Related]
2. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.
Vargas HA; Veeraraghavan H; Micco M; Nougaret S; Lakhman Y; Meier AA; Sosa R; Soslow RA; Levine DA; Weigelt B; Aghajanian C; Hricak H; Deasy J; Snyder A; Sala E
Eur Radiol; 2017 Sep; 27(9):3991-4001. PubMed ID: 28289945
[TBL] [Abstract][Full Text] [Related]
3. Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis.
Beer L; Sahin H; Bateman NW; Blazic I; Vargas HA; Veeraraghavan H; Kirby J; Fevrier-Sullivan B; Freymann JB; Jaffe CC; Brenton J; Miccó M; Nougaret S; Darcy KM; Maxwell GL; Conrads TP; Huang E; Sala E
Eur Radiol; 2020 Aug; 30(8):4306-4316. PubMed ID: 32253542
[TBL] [Abstract][Full Text] [Related]
4. High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.
Nougaret S; Lakhman Y; Gönen M; Goldman DA; Miccò M; D'Anastasi M; Johnson SA; Juluru K; Arnold AG; Sosa RE; Soslow RA; Vargas HA; Hricak H; Kauff ND; Sala E
Radiology; 2017 Nov; 285(2):472-481. PubMed ID: 28628421
[TBL] [Abstract][Full Text] [Related]
5. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
6. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.
Hyman DM; Long KC; Tanner EJ; Grisham RN; Arnold AG; Bhatia J; Phillips MF; Spriggs DR; Soslow RA; Kauff ND; Levine DA
Gynecol Oncol; 2012 Aug; 126(2):224-8. PubMed ID: 22579790
[TBL] [Abstract][Full Text] [Related]
8. Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction.
De Jong D; Otify M; Chen I; Jackson D; Jayasinghe K; Nugent D; Thangavelu A; Theophilou G; Laios A
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363568
[TBL] [Abstract][Full Text] [Related]
9. Survival time prediction in patients with high-grade serous ovarian cancer based on
He D; Zhang X; Chang Z; Liu Z; Li B
BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
[TBL] [Abstract][Full Text] [Related]
10. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
Marchetti C; De Leo R; Musella A; D'Indinosante M; Capoluongo E; Minucci A; Benedetti Panici P; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Nov; 25(12):3701-3708. PubMed ID: 30128899
[TBL] [Abstract][Full Text] [Related]
11. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
12. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Kwon JS; Tinker AV; Hanley GE; Pansegrau G; Sun S; Carey MS; Schrader I
Gynecol Oncol; 2019 Mar; 152(3):459-464. PubMed ID: 30876489
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
14. NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer.
Marchetti C; D'Indinosante M; Bottoni C; Di Ilio C; Di Berardino S; Costantini B; Minucci A; Vertechy L; Scambia G; Fagotti A
Sci Rep; 2021 May; 11(1):11125. PubMed ID: 34045513
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
16. Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
Marchetti C; Minucci A; D'Indinosante M; Ergasti R; Arcieri M; Capoluongo ED; Pietragalla A; Caricato C; Scambia G; Fagotti A
Gynecol Oncol; 2020 Sep; 158(3):740-746. PubMed ID: 32553590
[TBL] [Abstract][Full Text] [Related]
17. Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer.
Byun JM; Cho HJ; Lee DS; Yoon HK; Kim YN; Im DH; Kim DH; Lee KB; Sung MS; Jeong DH
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):107-111. PubMed ID: 36720520
[TBL] [Abstract][Full Text] [Related]
18. Misdiagnosis of High-grade Serous Ovarian Cancer With BRCA Mutation as Endometriotic Cyst Due to Its Unique Gross Morphology: A Case Report and Literature Review.
Ma Q; Yuan Y; Wang Y; Shao C; Feng W
Int J Gynecol Pathol; 2021 Mar; 40(2):165-168. PubMed ID: 31985581
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
[TBL] [Abstract][Full Text] [Related]
20.
Kansu B; Gardner J; Price-Tate R; Murch O; Murray A
J Obstet Gynaecol; 2021 Aug; 41(6):962-965. PubMed ID: 33228436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
